WO2009001764A1 - 統合失調症の治療または予防剤 - Google Patents

統合失調症の治療または予防剤 Download PDF

Info

Publication number
WO2009001764A1
WO2009001764A1 PCT/JP2008/061309 JP2008061309W WO2009001764A1 WO 2009001764 A1 WO2009001764 A1 WO 2009001764A1 JP 2008061309 W JP2008061309 W JP 2008061309W WO 2009001764 A1 WO2009001764 A1 WO 2009001764A1
Authority
WO
WIPO (PCT)
Prior art keywords
dysfunction syndrome
remedy
preventive
integration dysfunction
integration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/061309
Other languages
English (en)
French (fr)
Inventor
Satoru Yoshikawa
Hidenori Mochizuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to AU2008268202A priority Critical patent/AU2008268202B2/en
Priority to MX2009014181A priority patent/MX2009014181A/es
Priority to PL08777453T priority patent/PL2168580T3/pl
Priority to CN2008801034116A priority patent/CN101778632B/zh
Priority to JP2009520550A priority patent/JP5343848B2/ja
Priority to US12/664,686 priority patent/US8183256B2/en
Priority to EP08777453.5A priority patent/EP2168580B1/en
Priority to ES08777453.5T priority patent/ES2555785T3/es
Priority to KR20097026917A priority patent/KR101492029B1/ko
Priority to CA2691220A priority patent/CA2691220C/en
Publication of WO2009001764A1 publication Critical patent/WO2009001764A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　本発明は、統合失調症の特に陽性症状を治療することができ、また、統合失調症の一症状である認知障害等に関わる情報処理障害を引き起こさない、統合失調症の治療または予防剤を提供することを目的とする。 　すなわち、本発明は、下記化合物１に代表される特定のモルヒナン骨格を有する化合物、またはその薬理学的に許容される酸付加塩を有効成分とする統合失調症の治療または予防剤を提供した。 【化１】
PCT/JP2008/061309 2007-06-22 2008-06-20 統合失調症の治療または予防剤 Ceased WO2009001764A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2008268202A AU2008268202B2 (en) 2007-06-22 2008-06-20 Remedy or preventive for integration dysfunction syndrome
MX2009014181A MX2009014181A (es) 2007-06-22 2008-06-20 Remedio o preventivo para sindrome de disfuncion de integracion.
PL08777453T PL2168580T3 (pl) 2007-06-22 2008-06-20 Środek do leczenia lub zapobiegania schizofrenii
CN2008801034116A CN101778632B (zh) 2007-06-22 2008-06-20 综合失调症的治疗或预防药
JP2009520550A JP5343848B2 (ja) 2007-06-22 2008-06-20 統合失調症の治療または予防剤
US12/664,686 US8183256B2 (en) 2007-06-22 2008-06-20 Remedy or preventive for integration dysfunction syndrome
EP08777453.5A EP2168580B1 (en) 2007-06-22 2008-06-20 Remedy or preventive for schizophrenia
ES08777453.5T ES2555785T3 (es) 2007-06-22 2008-06-20 Remedio o preventivo para esquizofrenia
KR20097026917A KR101492029B1 (ko) 2007-06-22 2008-06-20 통합 실조증의 치료 또는 예방제
CA2691220A CA2691220C (en) 2007-06-22 2008-06-20 Remedy or preventive for integration dysfunction syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-164868 2007-06-22
JP2007164868 2007-06-22

Publications (1)

Publication Number Publication Date
WO2009001764A1 true WO2009001764A1 (ja) 2008-12-31

Family

ID=40185582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061309 Ceased WO2009001764A1 (ja) 2007-06-22 2008-06-20 統合失調症の治療または予防剤

Country Status (11)

Country Link
US (1) US8183256B2 (ja)
EP (1) EP2168580B1 (ja)
JP (1) JP5343848B2 (ja)
KR (1) KR101492029B1 (ja)
CN (1) CN101778632B (ja)
AU (1) AU2008268202B2 (ja)
CA (1) CA2691220C (ja)
ES (1) ES2555785T3 (ja)
MX (1) MX2009014181A (ja)
PL (1) PL2168580T3 (ja)
WO (1) WO2009001764A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093441A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 胆道疾患の治療又は予防剤
WO2012105475A1 (ja) 2011-01-31 2012-08-09 東レ株式会社 悪液質の治療又は予防剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI449704B (zh) * 2013-04-26 2014-08-21 Everlight Chem Ind Corp 嗎啡喃衍生物之結晶、其製造方法、及使用其之醫藥組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011289A1 (en) * 1997-09-02 1999-03-11 Toray Industries, Inc. Remedies for drug addiction
JP2000169476A (ja) * 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
WO2005085228A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. シクロアルカノピリジン誘導体
JP2005289886A (ja) * 2004-03-31 2005-10-20 Satoko Sawaguchi 自傷行動抑制薬
WO2007037513A1 (ja) * 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. アリール置換含窒素複素環化合物
WO2007100775A2 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01149788A (ja) 1987-12-08 1989-06-12 Chugai Pharmaceut Co Ltd 新規なモルヒネ誘導体
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
CN1111900A (zh) * 1993-06-30 1995-11-15 东丽株式会社 止咳药
KR100341950B1 (ko) 1993-07-19 2002-11-29 도레이 가부시끼가이샤 뇌세포보호제
DE69732868T2 (de) 1996-11-25 2006-04-13 Toray Industries, Inc. Mittel gegen Juckreiz
WO1999005146A1 (en) 1997-07-25 1999-02-04 Toray Industries, Inc. Hyponatremia remedies
JPH1192376A (ja) * 1997-09-17 1999-04-06 Toray Ind Inc ニコチン依存症治療剤
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
US6476208B1 (en) * 1998-10-13 2002-11-05 Genset Schizophrenia associated genes, proteins and biallelic markers
CN1204139C (zh) 1999-08-24 2005-06-01 东丽株式会社 神经性疼痛治疗剂
US8338442B2 (en) 2001-03-30 2012-12-25 Toray Industries, Inc. Remedies for psychoneurosis
JP4239592B2 (ja) 2001-05-08 2009-03-18 東レ株式会社 敗血症治療剤
US7553908B1 (en) * 2003-01-30 2009-06-30 Prc Desoto International, Inc. Preformed compositions in shaped form comprising polymer blends
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
AU2006221314B2 (en) 2005-03-10 2012-09-06 Toray Industries, Inc. Antipruritic agent for pruritus caused by multiple sclerosis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011289A1 (en) * 1997-09-02 1999-03-11 Toray Industries, Inc. Remedies for drug addiction
JP2000169476A (ja) * 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
WO2005085228A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. シクロアルカノピリジン誘導体
JP2005289886A (ja) * 2004-03-31 2005-10-20 Satoko Sawaguchi 自傷行動抑制薬
WO2007037513A1 (ja) * 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. アリール置換含窒素複素環化合物
WO2007100775A2 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAGLIARDI S. ET AL.: "Morphinan derivatives-A review of the recent patent literature", IDRUGS, vol. 6, no. 2, 2003, pages 129 - 137, XP008126753 *
IZENWASSER S. ET AL.: "Characterization of kappa-opioid receptor binding in human insular cortex", LIFE SCIENCES, vol. 65, no. 9, 1999, pages 857 - 862, XP008126754 *
MARGOLIS E.B. ET AL.: "Kappa opioids selectively control dopaminergic Neurons projecting to the prefrontal cortex", PNAS, vol. 103, no. 8, 21 February 2006 (2006-02-21), pages 2938 - 2942, XP008126746 *
TANAKA C. AND KATO R.: "NEW Yakurigaku, revised 3rd edition", 25 November 1996, NANKODO CO., LTD., pages: 268 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093441A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 胆道疾患の治療又は予防剤
US10131672B2 (en) 2010-01-29 2018-11-20 Toray Industries, Inc. Therapeutic or prophylactic agent for biliary diseases
WO2012105475A1 (ja) 2011-01-31 2012-08-09 東レ株式会社 悪液質の治療又は予防剤
US9006262B2 (en) 2011-01-31 2015-04-14 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia

Also Published As

Publication number Publication date
PL2168580T3 (pl) 2016-06-30
AU2008268202A1 (en) 2008-12-31
JP5343848B2 (ja) 2013-11-13
AU2008268202B2 (en) 2012-12-20
KR101492029B1 (ko) 2015-02-10
ES2555785T3 (es) 2016-01-08
KR20100023001A (ko) 2010-03-03
EP2168580A4 (en) 2011-08-17
US20100160364A1 (en) 2010-06-24
EP2168580A1 (en) 2010-03-31
EP2168580B1 (en) 2015-12-02
CA2691220A1 (en) 2008-12-31
CN101778632A (zh) 2010-07-14
CA2691220C (en) 2015-05-05
MX2009014181A (es) 2010-03-04
JPWO2009001764A1 (ja) 2010-08-26
US8183256B2 (en) 2012-05-22
CN101778632B (zh) 2012-02-29

Similar Documents

Publication Publication Date Title
WO2011012816A3 (fr) Formulation pharmaceutique
WO2007149797A3 (en) Use of organic compounds
WO2009064460A3 (en) Gastrointestinal delivery systems
TW200728307A (en) Novel spirochromanone derivatives
ECSP088923A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias
WO2009098715A3 (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
CR20110092A (es) Nuevos compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
WO2007087441A3 (en) Substituted aromatic compounds for inflammation and immune-related uses
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011011882A8 (en) Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
WO2007138472A3 (en) Triazolopyridazine derivatives
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
UA96458C2 (ru) Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
WO2007109230A3 (en) Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2008048589A3 (en) Compounds and methods for treatment of hcv
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2011064156A3 (de) Verfahren zur herstellung von methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamat und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
EP1900362A3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880103411.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777453

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009520550

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008268202

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2691220

Country of ref document: CA

Ref document number: 2008777453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/014181

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20097026917

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12664686

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2008268202

Country of ref document: AU

Date of ref document: 20080620

Kind code of ref document: A